Research Insight

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Research Insight sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials 1 currently recruiting 13 completed later-stage tilt top decile by trial count

Research Insight: 15 sponsored US clinical trials, 1 recruiting.

Research Insight sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 13 completed. 7 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye, with 2 trials.

Top-decile sponsor footprint

Research Insight ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

13 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

15 total, page 1 of 1

RECRUITING NA

The THINK Study Incidence of Neurotrophic Keratopathy)

NCT06482164

NOT YET RECRUITING Phase 4

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

NCT07276802

COMPLETED

2311 TURGOR Study -Surgical Efficiency and Postoperative Corneal Clarity With Near Physiologic vs High IOP Settings

NCT07144644

COMPLETED Phase 4

The COAT Trial: Cequa's Onset of Action Trial

NCT06482177

COMPLETED

The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction

NCT05346172

COMPLETED Phase 3

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

NCT05322148

COMPLETED

Evaluation of the Accuracy & Safety of the LaserArcs Nomogram

NCT05278442

COMPLETED Phase 4

The DEPOT Study (Dry Eye Prescription Options for Therapy)

NCT04911361

COMPLETED Phase 4

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

NCT04669561

COMPLETED

Vivity Insight: A Study of Patient Satisfaction and Visual Performance

NCT04495049

COMPLETED

Veracity Surgical: A Time/Motion and Quality of Care Study

NCT04337892

COMPLETED Phase 4

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

NCT04342988

COMPLETED Phase 4

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282

COMPLETED

The PanOptix Trifocal IOL: A Study of Patient Satisfaction, Visual Disturbances, and Uncorrected Visual Performance

NCT04146961

COMPLETED NA

Comparison of Pre-operative Measurements With Intraoperative Aberrometry in Predicting Correction for Low Toric Lens Correction in Cataract Surgery

NCT04247152

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 6

Therapeutic Areas

Where Research Insight enrollment is open (later-stage tilt)

1 recruiting of 15 indexed (7% open); 13 completed (87%).

Phase mix: 7 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Dry Eye (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Research Insight: open-pipeline peers nationwide

Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Research Insight sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 14.914.91515.1 0%10%20%30%40% Total trials Recruiting share Research InsightAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead PharmaceuticalsBaylor Breast Care CenterGeron CorporationGuerbetJoanne Kurtzberg, MD
Research Insight sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Research Insight sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

What to do with this Research Insight page

15 registered trials is a research-attention snapshot, not an endorsement of Research Insight or any single study.

  • 1 of Research Insight's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dry Eye is the condition Research Insight studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Research Insight pipeline card: 15 registered trials from official public datasets.Report a data error.